SCHEMBL1894062

SCHEMBL1894062

CCOC(=O)/C=C/c1ccc(C)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.77
CA1 P00915 1/20 0.77
CA2 P00918 1/20 0.77
CA7 P43166 1/20 0.77
CA9 Q16790 1/20 0.77
CA14 Q9ULX7 1/20 0.77
CYP3A4 P08684 2/20 0.67
TTR P02766 1/20 0.66
DPP4 P27487 1/20 0.66
MAOB P27338 2/20 0.59
FDPS P14324 1/20 0.56
MAPT P10636 3/20 0.55
RAB9A P51151 2/20 0.53
KMT2A Q03164 1/20 0.53
FOS P01100 1/20 0.51
JUN P05412 1/20 0.51
POLB P06746 1/20 0.51
ESR1 P03372 1/20 0.51
NPC1 O15118 1/20 0.50
APP P05067 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1894065 1.00 CA12 (0.77) CA12CA1CA2CA7CA9
SCHEMBL13957155 1.00 CA12 (0.77) CA12CA1CA2CA7CA9
SCHEMBL5059085 0.94 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL10939791 0.94 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL13957401 0.94 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL1260527 0.92 CA12 (0.83) CA12CA1CA2CA7CA9
SCHEMBL3143890 0.92 CA12 (0.83) CA12CA1CA2CA7CA9
SCHEMBL2075719 0.92 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL20857445 0.92 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL10505915 0.92 CA12 (0.67) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112067718-B Establishment method of muskiness rheumatalgia-relieving plaster volatile component fingerprint, standard fingerprint and application thereof 重庆希尔安药业有限公司 2022-07-29 CN claimed
CN-109796338-B Synthetic method of ozagrel intermediate p-bromomethyl cinnamate 深圳市第二人民医院 2022-05-06 CN claimed
CN-112067718-A Establishment method of muskiness rheumatalgia-relieving plaster volatile component fingerprint, standard fingerprint and application thereof 重庆希尔安药业有限公司 2020-12-11 CN claimed
US-20250051299-A1 PRODUCTION METHOD FOR FLUOROMETHYL DERIVATIVE DAIKIN INDUSTRIES, LTD. (JP) 2025-02-13 US disclosed
US-12162854-B2 Production method for fluoromethyl derivative DAIKIN INDUSTRIES, LTD. (JP) 2024-12-10 US disclosed
CN-115141098-B Method for preparing ozagrel intermediate through microchannel reaction 赤峰经方医药技术开发有限责任公司 2024-10-15 CN disclosed
US-20240188565-A1 GLOBODERA PALLIDA CONTROL AGENT NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (JP) 2024-06-13 US disclosed
EP-4298907-A1 GLOBODERA PALLIDA CONTROL AGENT NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (JP) 2024-01-03 EP disclosed
EP-2735562-B2 Estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS INC (US) 2023-11-15 EP disclosed
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-6342627-B1 ESTER INTERCHANGE WITH ALCOHOL IN THE PRESENCE OF LANTHANOIDE METAL ALKOXIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-01-29 US disclosed
US-5374641-A Thromboxane synthetase inhibitors, prostaglandin H2 antagonist , anticoagulants and antiallergens TERUMO KABUSHIKI KAISHA (JP) 1994-12-20 US disclosed
EP-0501876-A1 N-(3-pyridylalkyl)sulfonamide derivative and pharmaceutical preparation containing thereof TERUMO KABUSHIKI KAISHA (JP) 1992-09-02 EP disclosed
US-5043510-A Aqueous alkylation process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-08-27 US disclosed
US-4335054-A Process for the preparation of alkenylbenzenecarboxylic acid derivatives and alkenylnaphthalenecarboxylic acid derivatives CIBA-GEIGY CORPORATION (US) 1982-06-15 US disclosed
US-4260771-A VASODILATORS, ANTICOAGULANTS, IMMUNOLOGY MERCK & CO., INC. (US) 1981-04-07 US disclosed
US-4175203-A TREATMENT OF RENAL FAILURE AND TRANSPLANT REJECTION VASODILATORS MERCK & CO., INC. (US) 1979-11-20 US disclosed
US-4150235-A ANTIBODY INHIBITORS, HYPOTENSIVE AGENTS, DIURETICS, VASODILATOR MERCK & CO., INC. (US) 1979-04-17 US disclosed
US-4140861-A RENAL DISFUNCTION, ANTIBODY INHIBITORS MERCK & CO., INC. (US) 1979-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 CA12 2259/4885CA1 1289/4885CA2 425/4885
US-20240188565-A1 GLOBODERA PALLIDA CONTROL AGENT GHRHR, BRIX1, RBX1 CA12 1590/4885CA1 326/4885CA2 555/4885
US-12162854-B2 Production method for fluoromethyl derivative AFF1, AFF2, ROS1 CA12 2264/4885CA1 3273/4885CA2 3030/4885
US-20250051299-A1 PRODUCTION METHOD FOR FLUOROMETHYL DERIVATIVE AFF1, AFF2, ROS1 CA12 2264/4885CA1 3273/4885CA2 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.